Bradykinin Inhibits Development of Myocardial Infarction Through B2 Receptor Signalling by Increment of Regional Blood Flow Around the Ischaemic Lesions in Rats

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2003 Jan 11

PMID 12522094

Citations 10

Authors

Hiroshi Ito

Izumi Hayashi

Tohru Izumi

Masataka Majima

Affiliations

Soon will be listed here.

Abstract

1 To identify the roles of endogenous kinins in prevention of myocardial infarction (MI), we performed the permanent ligation of coronary artery in rats. 2 The size of MI 12, 24, and 48 h after coronary ligation in kininogen-deficient Brown Norway Katholiek (BN-Ka) rats was significantly larger (49.7+/-0.2%, 49.6+/-2%, and 51.1+/-1%, respectively) than that of kinin-replete Brown Norway Kitasato (BN-Ki) rats (42+/-2%, 38.5+/-4%, and 41.5+/-1%). 3 Hoe140, a bradykinin (BK) B(2) receptor antagonist injected (1.0 mg kg(-1), i.v.) half an hour before, and every 8 h after, coronary ligation, significantly increased the size of MI in Sprague-Dawley rats. Aprotinin, a kallikrein inhibitor, which was infused intravenously (10,000 Units kg(-1) h(-1)) with an osmotic mini-pump, significantly increased the size of an MI 24 h after ligation. 4 When evaluated using microspheres, the regional myocardial blood flow around the necrotic lesion in BN-Ka rats 6 h after ligation was reduced more than that in BN-Ki rats with MI by 41-46%. The same was true in Hoe140-treated BN-Ki rats. 5 FR190997, a nonpeptide B(2) agonist, which was infused (10 microg kg(-1) h(-1)) into the vena cava of BN-Ka rats for 24 h with an osmotic mini-pump, caused significant reduction in the size of MI (38+/-3%), in comparison with the size in vehicle solution-treated rats (51+/-3%). The size of MI in FR190997-treated BN-Ka rats was the same as in BN-Ki rats. 6 These results suggested that endogenous kinin has the capacity to reduce the size of MI via B(2) receptor signalling because of the increase in regional myocardial blood flow around the ischaemic lesion.

Citing Articles

Pretreatment of cardiac progenitor cells with bradykinin attenuates HO-induced cell apoptosis and improves cardiac function in rats by regulating autophagy.

Wu C, Zhou X, Li J, Qiang H, Wang Y, Li G Stem Cell Res Ther. 2021; 12(1):437.

PMID: 34353364 PMC: 8340370. DOI: 10.1186/s13287-021-02503-6.

Role of Kinins in Hypertension and Heart Failure.

Hamid S, Rhaleb I, Kassem K, Rhaleb N Pharmaceuticals (Basel). 2020; 13(11).

PMID: 33126450 PMC: 7692223. DOI: 10.3390/ph13110347.

Expression of B2 Receptor on Circulating CD34-Positive Cells and Outcomes of Myocardial Infarction.

Fu C, Cao Y, Yao Y, Tang S, Fan Q, Ling Y Dis Markers. 2019; 2019:7816438.

PMID: 31360266 PMC: 6644252. DOI: 10.1155/2019/7816438.

Modulation of cardiac vagal tone by bradykinin acting on nucleus ambiguus.

Brailoiu E, McGuire M, Shuler S, Deliu E, Barr J, Abood M Neuroscience. 2017; 365:23-32.

PMID: 28951324 PMC: 5798458. DOI: 10.1016/j.neuroscience.2017.09.034.

A Novel Category of Anti-Hypertensive Drugs for Treating Salt-Sensitive Hypertension on the Basis of a New Development Concept.

Katori M, Majima M Pharmaceuticals (Basel). 2016; 3(1):59-109.

PMID: 27713243 PMC: 3991021. DOI: 10.3390/ph3010059.

References

Hayashi I, Hoshiko S, Makabe O, Oh-ishi S . A point mutation of alanine 163 to threonine is responsible for the defective secretion of high molecular weight kininogen by the liver of brown Norway Katholiek rats. J Biol Chem. 1993; 268(23):17219-24. View

Hartman J, Wall T, Hullinger T, Shebuski R . Reduction of myocardial infarct size in rabbits by ramiprilat: reversal by the bradykinin antagonist HOE 140. J Cardiovasc Pharmacol. 1993; 21(6):996-1003. DOI: 10.1097/00005344-199306000-00022. View

Nolly H, Carretero O, Scicli A . Kallikrein release by vascular tissue. Am J Physiol. 1993; 265(4 Pt 2):H1209-14. DOI: 10.1152/ajpheart.1993.265.4.H1209. View

Nolly H, Carbini L, Scicli G, Carretero O, Scicli A . A local kallikrein-kinin system is present in rat hearts. Hypertension. 1994; 23(6 Pt 2):919-23. DOI: 10.1161/01.hyp.23.6.919. View

Wirth K, Hock F, Albus U, Linz W, Alpermann H, Anagnostopoulos H . Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies. Br J Pharmacol. 1991; 102(3):774-7. PMC: 1917928. DOI: 10.1111/j.1476-5381.1991.tb12249.x. View

Linz W, Wiemer G, Gohlke P, Unger T, Scholkens B . Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev. 1995; 47(1):25-49. View

Majima M, Katori M . Approaches to the development of novel antihypertensive drugs: crucial role of the renal kallikrein-kinin system. Trends Pharmacol Sci. 1995; 16(7):239-46. DOI: 10.1016/s0165-6147(00)89033-1. View

Menasche P, Kevelaitis E, Mouas C, GROUSSET C, PIWNICA A, Bloch G . Preconditioning with potassium channel openers. A new concept for enhancing cardioplegic protection?. J Thorac Cardiovasc Surg. 1995; 110(6):1606-13; discussion 1613-4. DOI: 10.1016/S0022-5223(95)70020-X. View

Majima M, Nishiyama K, Iguchi Y, Yao K, Ogino M, Ohno T . Determination of bradykinin-(1-5) in inflammatory exudate by a new ELISA as a reliable indicator of bradykinin generation. Inflamm Res. 1996; 45(8):416-23. DOI: 10.1007/BF02252938. View

10.

Kuribayashi Y, Katori M, Majima M, Yoshida K . Inhibitory effects of a phosphate diester of alpha-tocopherol and ascorbic acid (EPC-K1) on myocardial infarction in rats. Int J Tissue React. 1996; 18(2-3):73-9. View

11.

Yoshida H, Zhang J, Chao L, Chao J . Kallikrein gene delivery attenuates myocardial infarction and apoptosis after myocardial ischemia and reperfusion. Hypertension. 2000; 35(1 Pt 1):25-31. DOI: 10.1161/01.hyp.35.1.25. View

12.

Majima M, Hayashi I, Inamura N, Fujita T, Ogino M . A nonpeptide mimic of bradykinin blunts the development of hypertension in young spontaneously hypertensive rats. Hypertension. 2000; 35(1 Pt 2):437-42. DOI: 10.1161/01.hyp.35.1.437. View

13.

Tschope C, Heringer-Walther S, Koch M, Spillmann F, Wendorf M, Leitner E . Upregulation of bradykinin B1-receptor expression after myocardial infarction. Br J Pharmacol. 2000; 129(8):1537-8. PMC: 1571999. DOI: 10.1038/sj.bjp.0703239. View

14.

Shinmura K, Tang X, Wang Y, Xuan Y, Liu S, Takano H . Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits. Proc Natl Acad Sci U S A. 2000; 97(18):10197-202. PMC: 27805. DOI: 10.1073/pnas.97.18.10197. View

15.

Matsumura K, Komori S, Takusagawa M, Osada M, Tanabe F, Itoh M . Protein kinase C is involved in cardioprotective effects of ischemic preconditioning on infarct size and ventricular arrhythmia in rats in vivo. Mol Cell Biochem. 2001; 214(1-2):39-45. DOI: 10.1023/a:1007119622322. View

16.

Sharma A, Singh M . Protein kinase C activation and cardioprotective effect of preconditioning with oxidative stress in isolated rat heart. Mol Cell Biochem. 2001; 219(1-2):1-6. DOI: 10.1023/a:1011038531656. View

17.

Aramori I, Zenkoh J, Morikawa N, Asano M, Hatori C, Sawai H . Nonpeptide mimic of bradykinin with long-acting properties at the bradykinin B2 receptor. Mol Pharmacol. 1997; 52(1):16-20. DOI: 10.1124/mol.52.1.16. View

18.

Yang X, Liu Y, Scicli G, Webb C, Carretero O . Role of kinins in the cardioprotective effect of preconditioning: study of myocardial ischemia/reperfusion injury in B2 kinin receptor knockout mice and kininogen-deficient rats. Hypertension. 1997; 30(3 Pt 2):735-40. DOI: 10.1161/01.hyp.30.3.735. View

19.

Ito K, Zhu Y, Zhu Y, Gohlke P, Unger T . Contribution of bradykinin to the cardioprotective action of angiotensin converting enzyme inhibition in hypertension and after myocardial infarction. Jpn J Pharmacol. 1998; 75(4):311-8. DOI: 10.1254/jjp.75.311. View

20.

Hamilton K, Powers S, Sugiura T, Kim S, Lennon S, Tumer N . Short-term exercise training can improve myocardial tolerance to I/R without elevation in heat shock proteins. Am J Physiol Heart Circ Physiol. 2001; 281(3):H1346-52. DOI: 10.1152/ajpheart.2001.281.3.H1346. View